I'm in this for the long haul but the signs aren't good. With the biotech sector reviving, few seem interested in PAR. This is despite a huge TAM and what seem to be reasonable prospects of approval. The main thing which has dragged the SP down is poor capital management. The board have had ample opportunities to raise money at a reasonable SP but seem to never raise enough to remove the black cloud of CR speculation. A great idea very badly managed.
PAR. SP, page-694
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $288.5K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 130626 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |